The pharmacokinetics of epirubicin and docetaxel combination in rats

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 6, 1999, Pages 469-474

  Sandström, Marie ^a   Simonsen, Lena E ^a   Freijs, Agneta ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Docetaxel; Epirubicin; Interaction Pharmacokinetics; Rats

Indexed keywords

DOCETAXEL; EPIRUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; COMPARTMENT MODEL; CONCENTRATION RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPIRUBICIN; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; SOFTWARE; TAXOIDS;

EID: 0032708724     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051120     Document Type: Article

References (27)

1. 1. Baker S (1997) Drug interactions with the taxanes. Pharmacotherapy 17 (5 pt 2): 126S
2. 2. Bartlett NL, BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835
3. 3. Beal SL, Sheiner LB (1994) NONMEM Users Guides. NONMEM Project group, University of California, San Francisco
4. 4. Bissery MC, Nohynek G, Sanderink G-J, Lavelle F (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6: 339
5. 5. Colombo T, Gonzales Paz. O, Zucchietti M, Maneo M, Sessa C, Goldhirsch A, D'Incalci M (1996) Paclitaxel induces significant changes in epidoxorubicin disribution in mice. Ann Oncol 7: 801
6. 6. Coukell AJ, Faulds D (1997) Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 53: 453
7. 7. Czejka M, Bandak S, Simon D, Schüller J, Weiss C, Schernhammer E (1995) Pharmacokinetic interaction between 4-epidoxorubicin and the multidrug resistant reverting agent quinine. Z Naturforsch [C] 50: 565
8. 8. Eisenhauer EA, Vermorken JB (1998) The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55: 5
9. 9. Friche E, Jensen PB, Sehested M, Demant EJ, Nissen NN (1990) The solvents cremophor EL and tween 80 modulate daunorubicin resistance in the multidrug resistant erlich ascites tumor. Cancer Commun 2: 297
10. 10. Hunter J, Hirst BH, Simmons NL (1993) Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 10: 743
11. 11. Israel M, Pegg WJ, Wilkinson PM, Garnick MB (1978) Liquid chromatographic analysis of Adriamycin and metabolites in biological fluids. J Liq Chromatogr 1: 795
12. 12. Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Petersen D, Gjedde SB, Sandberg E, Rose C, Nielsen OS, Mouridsen HT (1991) A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 28: 465
13. 13. Jonsson EN, Karlsson MO (1998) Xpose - an Splus based population pharmacokinetic-pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58: 51
14. 14. Kerbrat P, Fumoleau JP, Guastalla H, Roché T, Delozier I, Marcillac M, Bardonnet M (1997) Epirubicin in combination with docetaxel as first-line chemotherapy of metastatic breast cancer: preliminary results of phase I dose-finding study. American Society of Clinical Oncology Annual Meeting, Abstract 690
15. 15. Launay MC, Milano G, Illiadis A, Frenay M, Namer N (1989) A limited sampling procedure for estimating Adriamycin pharmacokinetics in cancer patients. Br J Cancer 90: 89
16. 16. Lindén CJ (1989) Toxicity of intraperitoneally administered anti tumour drugs in athymic rats. In vivo 3: 259
17. 17. Marre F, Sanderink G-J, De Sousa G, Gaillard C, Martinet M, Rahmani G (1996) Hepatic biotransformation of docetaxel (Taxotere®) in vitro: involvement of the CYP3 A subfamily in humans. Cancer Res 56: 1296
18. 18. Mayhew EG, Lasic D, Babbar S, Martin FJ (1992) Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycolderivatized phospholipid. Int J Cancer 51: 302
19. 19. Plosker GL, Faulds D (1993) Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer therapy. Drugs 45: 788
20. 20. Robert J (1980) Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liq Chromatogr 3: 1561
21. 21. Robert J (1993) Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 45 [Suppl 2]: 20
22. 22. Robert J (1994) Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 26: 428
23. 23. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA (1994) The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74: 834
24. 24. Sandström M, Freijs A, Larsson R, Nygren P, Fjällskog M-L, Bergh J, Karlsson MO (1996) Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 14: 1581
25. 25. Verweij J, Clavel M, Chevalier B (1994) Paclitaxel (Taxol™) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5: 495
26. 26. Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK (1993) High-performance liquid Chromatographic procedure for the quantitative determination of paclitaxel (Taxol®) in human plasma. J Chromatogr 621: 231
27. 27. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello I (1990) Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50: 4199